scm logo

- Research initiative for the 2024 Pan-Ministry Regenerative Medical Technology Development Project

- Results of strategic technology commercialization with SCM Life Science, Inha University, and Inha University Hospital

SCM Life Science revealed on April 29 that on the 26th, the research project 'Development and validation of a stem cell
multi-process platform for treating autoimmune diseases' was officially chosen and a research agreement was signed
for the 2024 Pan-Ministry Regenerative Medical Technology Development Project.

The Pan-Ministry Regenerative Medical Technology Development Project, supported by both the Ministry of Science and
ICT and the Ministry of Health and Welfare, aims to aid the entire cycle from discovering core and source technologies
in the field to reaching the clinical stage of treatments and treatment technologies.

This research project between SCM Life Science, Inha University, and Inha University Hospital is strategically aimed
at technology commercialization. It will be carried out jointly by teams led by professors Boo Jiyoon, Kwon Soonjo,
and Baek Youngbin from the Department of Biotechnology at Inha University and professor Jeon Myung-shin from
the Translational Research Center at Inha University Hospital.

The main objective of the research project is to produce customized treatments and develop innovative regenerative
medicine technologies by combining their respective expertise through collaboration between industry, academia, and medicine.

SCM Life Science specializes in developing stem cell therapies and possesses proprietary technology for isolating high-purity stem cells.
Their core technology, the layer separation culture method, is recognized for its ability to address heterogeneity issues seen with existing
stem cell isolation methods. In addition, the company has established a mass culture system to ensure stem cell manufacturing capabilities.

The agreement for the Pan-Ministry Regenerative Medical Technology Development Project signifies a fusion of SCM Life Science’s high-purity stem cell
isolation technology with the development of continuous production process technology, using microfluidic chips and nanoreceptors, along with an effectiveness
evaluation platform using patient blood from hospitals. This collaboration is seen as highly promising for developing regenerative medicine convergence technology.

In addition, the project aims to develop convergence technologies that not only maximize efficacy but also simplify and standardize the manufacturing process of
stem cell treatments through efficient collaboration among industry, academia, and medicine. It is anticipated that this will serve as a foundational technology for
the early commercialization of stem cell treatments, align with global regulatory trends, and enable the securing of domestic and global patents.

"We aim to transcend the mere development of high-purity and highly efficient mesenchymal stem cells. Our goal is to establish a platform technology for
supplying customized stem cell treatments for autoimmune diseases, ensuring high price competitiveness through the development of automated mass
production processes and treatments compliant with global regulatory trends," said SCM Life Science, expressing their ambitious vision.

Source : THE BIO(https://www.thebionews.net/news/articleView.html?idxno=4804)